biologic

Cimzia

certolizumab pegol

Loss of exclusivityMarch 2031projected — 12-year biologic exclusivity estimate
CompanyUCBView the full company profile on CliffBio

Drug detail

Brand nameCimzia
Active ingredientcertolizumab pegol
Strength200MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMarch 2019
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Not found